Form 4: Acumen Pharmaceuticals Executive Acquires Shares and Options

Acumen Pharmaceuticals' President and CDO, James J. Doherty, acquired 62,600 shares of common stock and 93,300 stock options on January 6, 2025.

Summary

• James J. Doherty, President and CDO of Acumen Pharmaceuticals, acquired 62,600 shares of common stock on January 6, 2025.
• These shares were received as a restricted stock unit (RSU) award, with vesting occurring in three equal annual installments starting one year after the grant date.
• Doherty also acquired 93,300 employee stock options on the same date, with an exercise price of $1.85 per share.
• The options vest in 48 equal monthly installments, becoming fully vested on the fourth anniversary of the grant date.
• Both the RSU and option vesting are contingent on Doherty's continuous service with the company.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns executive interests with shareholder value. The vesting schedules indicate a long-term commitment.

Positives

• The acquisition of shares and options by a key executive like the President and CDO can be seen as a positive sign of confidence in the company's future.
• The vesting schedules for both the RSUs and options incentivize long-term commitment from the executive.

Risks

• The vesting of the shares and options is contingent on the executive's continued employment, which introduces a risk of forfeiture if the executive leaves the company before vesting is complete.

Future Outlook

The vesting schedules for the acquired shares and options suggest a long-term commitment from the executive to the company.

Industry Context

This type of stock and option grant is a common practice in the pharmaceutical industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option and RSU grants are standard practice for executive compensation in the biotech and pharmaceutical industries.
• Vesting schedules of 3-4 years are also typical for these types of grants, aligning with long-term value creation goals.
• Companies like Biogen, Amgen, and Regeneron also use similar equity-based compensation strategies for their executives.

Stakeholder Impact

• Shareholders may view this as a positive sign of executive commitment.
• Employees may see this as a positive sign of the company's growth and stability.

Key Dates

Keywords

Acumen Pharmaceuticals, stock options, restricted stock units, executive compensation, insider trading, share acquisition, vesting